메뉴 건너뛰기




Volumn 90, Issue 2-3, 2009, Pages 277-285

Price control as a strategy for pharmaceutical cost containment-What has been achieved in Norway in the period 1994-2004?

Author keywords

Cost control; Generic drugs; Norway; Reimbursement

Indexed keywords

ARTICLE; DRUG COST; ECONOMIC ASPECT; INTERVIEW; NORWAY; PRESCRIPTION;

EID: 63749087204     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2008.09.018     Document Type: Article
Times cited : (67)

References (35)
  • 1
    • 0041530262 scopus 로고    scopus 로고
    • The drug budget silo mentality in Europe: an overview
    • Garrison L., and Towse A. The drug budget silo mentality in Europe: an overview. Value in Health 6 Suppl. 1 (2003) 1-9
    • (2003) Value in Health , vol.6 , Issue.SUPPL. 1 , pp. 1-9
    • Garrison, L.1    Towse, A.2
  • 2
    • 23844484540 scopus 로고    scopus 로고
    • Cost-containment as part of pharmaceutical policy
    • Almarsdóttir A.B., and Traulsen J.M. Cost-containment as part of pharmaceutical policy. Pharmacy World & Science 27 3 (2005) 144-148
    • (2005) Pharmacy World & Science , vol.27 , Issue.3 , pp. 144-148
    • Almarsdóttir, A.B.1    Traulsen, J.M.2
  • 3
    • 0037239005 scopus 로고    scopus 로고
    • European healthcare policies for controlling drug expenditure
    • Ess S.M., Schneeweiss S., and Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21 2 (2003) 89-103
    • (2003) Pharmacoeconomics , vol.21 , Issue.2 , pp. 89-103
    • Ess, S.M.1    Schneeweiss, S.2    Szucs, T.D.3
  • 4
    • 34250736162 scopus 로고    scopus 로고
    • Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis
    • Garattini L., Cornago D., and Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy 82 3 (2007) 330-339
    • (2007) Health Policy , vol.82 , Issue.3 , pp. 330-339
    • Garattini, L.1    Cornago, D.2    Compadri, P.3
  • 5
    • 33745011139 scopus 로고    scopus 로고
    • Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies
    • Art. No.: CD005979. doi:10.1002/14651858.CD005979
    • Aaserud M., Dahlgren A.T., Kösters J.P., Oxman A.D., Ramsay C., and Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews 2 (2006) Art. No.: CD005979. doi:10.1002/14651858.CD005979
    • (2006) Cochrane Database of Systematic Reviews , Issue.2
    • Aaserud, M.1    Dahlgren, A.T.2    Kösters, J.P.3    Oxman, A.D.4    Ramsay, C.5    Sturm, H.6
  • 6
    • 36348988465 scopus 로고    scopus 로고
    • International comparison of generic medicine prices
    • Simoens S. International comparison of generic medicine prices. Current Medical Research and Opinion 23 11 (2007) 2647-2654
    • (2007) Current Medical Research and Opinion , vol.23 , Issue.11 , pp. 2647-2654
    • Simoens, S.1
  • 7
    • 0036688443 scopus 로고    scopus 로고
    • Comparative approaches to pharmaceutical price regulation in the European Union
    • Mrazek M.F. Comparative approaches to pharmaceutical price regulation in the European Union. Croatian Medical Journal 43 4 (2002) 453-461
    • (2002) Croatian Medical Journal , vol.43 , Issue.4 , pp. 453-461
    • Mrazek, M.F.1
  • 8
    • 33847333167 scopus 로고    scopus 로고
    • Reference drug programs: effectiveness and policy implications
    • Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy 81 1 (2007) 17-28
    • (2007) Health Policy , vol.81 , Issue.1 , pp. 17-28
    • Schneeweiss, S.1
  • 9
    • 0031730424 scopus 로고    scopus 로고
    • Pharmaceutical reference prices. How do they work in practice?
    • Dickson M., and Redwood H. Pharmaceutical reference prices. How do they work in practice?. Pharmacoeconomics 14 5 (1998) 471-479
    • (1998) Pharmacoeconomics , vol.14 , Issue.5 , pp. 471-479
    • Dickson, M.1    Redwood, H.2
  • 10
    • 0036060499 scopus 로고    scopus 로고
    • Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes
    • Ioannides-Demos L.L., Ibrahim J.E., and McNeil J.J. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 20 9 (2002) 577-591
    • (2002) Pharmacoeconomics , vol.20 , Issue.9 , pp. 577-591
    • Ioannides-Demos, L.L.1    Ibrahim, J.E.2    McNeil, J.J.3
  • 11
    • 0034680689 scopus 로고    scopus 로고
    • Review of the literature on reference pricing
    • López-Casasnovas G., and Puig-Junoy J. Review of the literature on reference pricing. Health Policy 54 2 (2000) 87-123
    • (2000) Health Policy , vol.54 , Issue.2 , pp. 87-123
    • López-Casasnovas, G.1    Puig-Junoy, J.2
  • 12
    • 0033065043 scopus 로고    scopus 로고
    • Outstanding regulatory aspects in the European pharmaceutical market
    • Kanavos P., and Mossialos E. Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconomics 15 6 (1999) 519-533
    • (1999) Pharmacoeconomics , vol.15 , Issue.6 , pp. 519-533
    • Kanavos, P.1    Mossialos, E.2
  • 14
    • 2042503055 scopus 로고    scopus 로고
    • Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia
    • Morgan S.G., Agnew J.D., and Barer M.L. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia. Health Policy 68 3 (2004) 299-307
    • (2004) Health Policy , vol.68 , Issue.3 , pp. 299-307
    • Morgan, S.G.1    Agnew, J.D.2    Barer, M.L.3
  • 15
    • 0026600567 scopus 로고
    • Norway's pivotal role in regulatory health economics and pharmaceutical cost containment - what can other countries learn?
    • Andersson F. Norway's pivotal role in regulatory health economics and pharmaceutical cost containment - what can other countries learn?. Health Policy 21 1 (1992) 17-34
    • (1992) Health Policy , vol.21 , Issue.1 , pp. 17-34
    • Andersson, F.1
  • 16
    • 0031974129 scopus 로고    scopus 로고
    • The impact of European harmonisation on Norwegian drug policy
    • Norris P. The impact of European harmonisation on Norwegian drug policy. Health Policy 43 1 (1998) 65-81
    • (1998) Health Policy , vol.43 , Issue.1 , pp. 65-81
    • Norris, P.1
  • 17
    • 27744457330 scopus 로고    scopus 로고
    • Deregulating the pharmacy market: the case of Iceland and Norway
    • Anell A. Deregulating the pharmacy market: the case of Iceland and Norway. Health Policy 75 1 (2005) 9-17
    • (2005) Health Policy , vol.75 , Issue.1 , pp. 9-17
    • Anell, A.1
  • 18
    • 67649188454 scopus 로고    scopus 로고
    • The Norwegian Association of Pharmaceutical Manufacturers, accessed 20.02.2008
    • The Norwegian Association of Pharmaceutical Manufacturers. Facts and figures. http://lmi.no/FullStory.aspx?m=146 [accessed 20.02.2008].
    • Facts and figures
  • 19
    • 63749102538 scopus 로고    scopus 로고
    • Patented Medicine Prices Review Board. Foreign price trends for patented medicines. PMPRB study series S-0216. Ontario; 2002.
    • Patented Medicine Prices Review Board. Foreign price trends for patented medicines. PMPRB study series S-0216. Ontario; 2002.
  • 20
    • 63749110255 scopus 로고    scopus 로고
    • Granum L. Economical effects of the reference price system. Report 04/1999. Oslo: The National Insurance Administration; 1999 [in Norwegian].
    • Granum L. Economical effects of the reference price system. Report 04/1999. Oslo: The National Insurance Administration; 1999 [in Norwegian].
  • 21
    • 63749121475 scopus 로고    scopus 로고
    • Evaluation of the reference price system
    • Report 44/. Oslo;, in Norwegian
    • Econ. Evaluation of the reference price system. Report 44/2000. Oslo; 2000 [in Norwegian].
    • (2000) , pp. 2000
    • Econ1
  • 22
  • 23
    • 63749086396 scopus 로고    scopus 로고
    • The Norwegian Medicines Agency, in Norwegian, accessed 29.09.2008
    • The Norwegian Medicines Agency. Reassessment of maximum PPP of prescription medicines [in Norwegian]. http://www.legemiddelverket.no/templates/InterPage_38821.aspx [accessed 29.09.2008].
    • Reassessment of maximum PPP of prescription medicines
  • 24
    • 63749124682 scopus 로고    scopus 로고
    • 02-39: Lov om apotek (apotekloven)
    • LOV, in Norwegian, 2000
    • LOV 2000-06-02-39: Lov om apotek (apotekloven). Oslo: Ministry of Health and Care Services; 2000 [in Norwegian].
    • (2006) Oslo: Ministry of Health and Care Services
  • 25
    • 14944362843 scopus 로고    scopus 로고
    • Evaluation of the pharmaceutical legislation and the index price system
    • Report 10/. Oslo;, in Norwegian
    • Econ. Evaluation of the pharmaceutical legislation and the index price system. Report 10/2004. Oslo; 2004 [in Norwegian].
    • (2004) , pp. 2004
    • Econ1
  • 26
    • 63749120385 scopus 로고    scopus 로고
    • Dalen DM. The pharmaceutical market after the pharmacy reform. Regulation, market structure and competition. Skriftserie 11/2003. Oslo: Helseøkonomisk forskningsprogram; 2003 [in Norwegian].
    • Dalen DM. The pharmaceutical market after the pharmacy reform. Regulation, market structure and competition. Skriftserie 11/2003. Oslo: Helseøkonomisk forskningsprogram; 2003 [in Norwegian].
  • 29
    • 33750066296 scopus 로고    scopus 로고
    • Price regulation and generic competition in the pharmaceutical market
    • Dalen D.M., Strøm S., and Haabeth T. Price regulation and generic competition in the pharmaceutical market. The European Journal of Health Economics 7 3 (2006) 208-214
    • (2006) The European Journal of Health Economics , vol.7 , Issue.3 , pp. 208-214
    • Dalen, D.M.1    Strøm, S.2    Haabeth, T.3
  • 30
    • 26044436000 scopus 로고    scopus 로고
    • Access to drugs: patent-drug price board to review guidelines
    • Sibbald B. Access to drugs: patent-drug price board to review guidelines. Canadian Medical Association Journal 172 9 (2005) 1169
    • (2005) Canadian Medical Association Journal , vol.172 , Issue.9 , pp. 1169
    • Sibbald, B.1
  • 31
    • 33749527199 scopus 로고    scopus 로고
    • A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences
    • Lexchin J. A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences. Health Policy 79 2-3 (2006) 214-220
    • (2006) Health Policy , vol.79 , Issue.2-3 , pp. 214-220
    • Lexchin, J.1
  • 32
    • 14944376871 scopus 로고    scopus 로고
    • The impact of price regulation on the launch delay of new drugs - evidence from twenty-five major markets in the 1990s
    • Danzon P.M., Wang Y.R., and Wang L. The impact of price regulation on the launch delay of new drugs - evidence from twenty-five major markets in the 1990s. Health Economics 14 3 (2005) 269-292
    • (2005) Health Economics , vol.14 , Issue.3 , pp. 269-292
    • Danzon, P.M.1    Wang, Y.R.2    Wang, L.3
  • 33
    • 0031943370 scopus 로고    scopus 로고
    • Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist
    • Moen E., Toverud E.L., Grund J., and Brinchmann S. Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist. Pharmacy World & Science 20 3 (1998) 107-112
    • (1998) Pharmacy World & Science , vol.20 , Issue.3 , pp. 107-112
    • Moen, E.1    Toverud, E.L.2    Grund, J.3    Brinchmann, S.4
  • 34
    • 0036435031 scopus 로고    scopus 로고
    • Pharmaceutical cost containment with reference-based pricing: time for refinements
    • Schneeweiss S., Maclure M., Dormuth C., and Avorn J. Pharmaceutical cost containment with reference-based pricing: time for refinements. Canadian Medical Association Journal 167 11 (2002) 1250-1251
    • (2002) Canadian Medical Association Journal , vol.167 , Issue.11 , pp. 1250-1251
    • Schneeweiss, S.1    Maclure, M.2    Dormuth, C.3    Avorn, J.4
  • 35
    • 33745956031 scopus 로고    scopus 로고
    • A re-examination of the impact of reference pricing on antihypertensive drug plan expenditures in British Columbia
    • Grootendorst P., and Stewart D. A re-examination of the impact of reference pricing on antihypertensive drug plan expenditures in British Columbia. Health Economics 15 7 (2006) 735-742
    • (2006) Health Economics , vol.15 , Issue.7 , pp. 735-742
    • Grootendorst, P.1    Stewart, D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.